In a report released today, Bruce Jackson from Benchmark Co. reiterated a Buy rating on Harvard Bioscience (HBIO – Research Report), with a price target of $7.00. The company’s shares opened today at $5.99.
Jackson covers the Healthcare sector, focusing on stocks such as Exact Sciences, Harvard Bioscience, and Clene. According to TipRanks, Jackson has an average return of -4.4% and a 37.01% success rate on recommended stocks.
Harvard Bioscience has an analyst consensus of Moderate Buy, with a price target consensus of $7.00.
See the top stocks recommended by analysts >>
Based on Harvard Bioscience’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $29.98 million and a net profit of $622 thousand. In comparison, last year the company earned a revenue of $28.78 million and had a GAAP net loss of $6.88 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Harvard Bioscience, Inc. develops, manufactures, and markets broad range of specialized products, primarily apparatus and scientific instruments. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.
Read More on HBIO:
- Harvard Bioscience Set to Join Russell 2000® and 3000® Indexes
- Harvard Bioscience appoints Cote as Chief Financial Officer, Treasurer
- Harvard Bioscience Appoints Jennifer Cote as Chief Financial Officer
- Harvard Bioscience to Present at Sidoti Micro Cap Virtual Conference May 10th, 2023
- Harvard Bioscience price target raised to $7 from $4 at Benchmark
